PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 11, 2026Haematologica1 citationsOpen Access

Disease course of FLT3 mutated extramedullary acute myeloid leukemia and efficacy of gilteritinib

View Full Paper
FAFrancesco AngotziEBErika BorlenghiCSC. Sartor

Key Points

  • To understand the disease progression of FLT3 mutated extramedullary acute myeloid leukemia and assess the effectiveness of gilteritinib treatment.
  • Analyzed disease progression in FLT3 mutated patients
  • Evaluated responses to gilteritinib treatment
  • Monitored clinical outcomes and side effects
  • Gilteritinib showed promising efficacy in managing FLT3 mutated cases
  • Patients experienced varied responses, indicating potential benefits in some
  • Extramedullary disease remained a concern, needing more research

Abstract

Not available.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Angotzi et al. (2026) studied this question.

synapsesocial.com/papers/69d9e5ec78050d08c1b7627ehttps://doi.org/10.3324/haematol.2026.300540
Ask AI
Helpful
Bookmark
Share
View Full Paper